TABLE 1.
Tissue source | Cell line | 5-Aza-CdR treatment | Expression of:
|
|
---|---|---|---|---|
ARF | INK4a | |||
Colon | HCT116 | − | + | + |
+ | + | + | ||
SW48 | − | + | − | |
+ | + | + | ||
HCT15 | − | − | − | |
+ | + | + | ||
LoVo | − | − | − | |
SW837 | − | + | − | |
HT-29 | − | + | − | |
Cervix | C-33A | − | + | + |
Bladder | 5637 | − | + | + |
T24 | − | + | − | |
+ | + | + | ||
J82 | − | + | + | |
Lymphoid | Raji | − | + | − |
+ | + | + | ||
CA46 | − | + | − | |
HL-60 | − | + | − | |
Liver | Hep 3B | − | + | + |
Pancreas | CFPac-1 | − | + | − |
+ | + | + |
Expression of the transcript indicated was scored as present (+) or absent (−) after Southern hybridization with oligonucleotide probes specific for the first exon of each gene. 5-Aza-CdR treatments were at 1.0 μM for 72 h.